IDENTIFICATION AND ANTIFUNGAL SUSCEPTIBILITY OF CANDIDA SPECIES IN VULVOVAGINAL CANDIDIASIS FEMALE PATIENTS AT A VIETNAMESE HOSPITAL
DOI:
https://doi.org/10.22159/ajpcr.2025v18i6.54611Keywords:
antifungal susceptibility, azole, Candida albicans, Candida non-albicans, CHROM-agar, identificationAbstract
Objective: This study aimed to investigate the prevalence rate of Candida species isolated from women clinically suspected of having vulvovaginal candidiasis and assess susceptibility patterns against commonly used antifungal agents.
Methods: This was a cross-sectional, hospital-based study conducted for candidiasis at the vaginal level from May 2023 to December 2023. A total of 146 women clinically suspected of infecting Candida spp. were subjected to the identification employing disc diffusion methods. Antifungal susceptibility assay was conducted on Candida isolates against four commonly used antifungal drugs of the azole group.
Results: Of the 146 Candida strain isolates from vaginal swabs, Candida albicans was the most prevalent occurrence accounting for 68.75%, followed by Candida glabrata (11.88%) and Candida parapsilosis (11.25%). Of the 110 Candida albicans isolates, 108 cases were sensitive to clotrimazole, followed by miconazole (41 cases). Meanwhile, of the 50 non-albicans isolates, all cases were susceptible to clotrimazole, followed by miconazole (38 cases). Different rates of resistance against itraconazole and fluconazole (but not clotrimazole and miconazole) were documented in all isolated non-albicans strains. The 96 Candida albicans cases exhibited resistance to fluconazole, followed by miconazole (5 cases) and clotrimazole (1 case).
Conclusion: These findings provided data for better disease management, aiming at reducing morbidity and mortality.
Downloads
References
Spampinato C, Leonardi D. Candida infections, causes, targets, and resistance mechanisms: Traditional and alternative antifungal agents. Biomed Res Int. 2013;2013:204237. doi: 10.1155/2013/204237, PMID 23878798
Talapko J, Juzbašić M, Matijević T, Pustijanac E, Bekić S, Kotris I, et al. Candida albicans-the virulence factors and clinical manifestations of infection. J Fungi (Basel). 2021 Jan 22;7(2):79. doi: 10.3390/ jof7020079, PMID 33499276
Turner SA, Butler G. The Candida pathogenic species complex. Cold Spring Harb Perspect Med. 2014 Sep 1;4(9):a019778. doi: 10.1101/ cshperspect.a019778, PMID 25183855
Zeng X, Zhang Y, Zhang T, Xue Y, Xu H, An R. Risk factors of vulvovaginal candidiasis among women of reproductive age in Xi’an: A cross-sectional study. Biomed Res Int. 2018 Jun 7;2018:9703754. doi: 10.1155/2018/9703754, PMID 29977925
Anurova MN, Bakhrushina EO, Shumkova MM, Demina NB, Krasnyuk II. The development and study of the toxicity of suppositories with a modified substance of interferon alfa-2b. Int J App Pharm. 2023 Mar 7;15:140-145. doi: 10.22159/ijap.2023v15i2.46368
Kushwaha V, Agrawal P, Fatma Khan N, Shivhare DP, Kumar A, Sharma H. Drug prescribing pattern of various antifungal drugs for dermatophytosis in a tertiary healthcare and teaching Hospital. Int J Pharm Pharm Sci. 2023 Apr 1;15:16-21. doi: 10.22159/ ijpps.2023v15i4.47457
Vitiello A, Ferrara F, Boccellino M, Ponzo A, Cimmino C, Comberiati E, et al. Antifungal drug resistance: An emergent health threat. Biomedicines. 2023 Mar 31;11(4):1063. doi: 10.3390/ biomedicines11041063, PMID 37189681
Siddiqui R, Mendiratta DK, Siddiqui AF, Rukadikar A. A study of the association between virulence factors and antifungal susceptibility profile of Candida species recovered from cases of vulvovaginal candidiasis. J Fam Med Prim Care. 2023 Jan;12(1):152-159. doi: 10.4103/jfmpc.jfmpc-1479-22, PMID 37025213
El-Garhy OH. An overview of the azoles of interest. Int J Curr Pharm Res. 2015;7(1):1-6.
Preethi S, Kumar H, Rawal VB, Ajmeer R, Jain V. Overview of mitoxantrone-a potential candidate for treatment of breast cancer. Int J Appl Pharm. 2022 Mar 7;14:10-22.
Bradshaw C, Ison C, Wilson J, Skov Jensen J. Laboratory and point-of-care diagnostic testing for sexually transmitted infections, including HIV. In: Candidiasis. Cha. 11. Geneva: World Health Organization; 2023.
Padilha CM, Picciani BL, Santos BM, Silva Júnior A, Dias EP. Comparative analysis of Grams method and PAS for the identification of Candida spp. Samples from the oral mucosa. J Bras Patol Med Lab. 2014;50(5):352. doi: 10.5935/1676-2444.20140039
Nadeem SG, Hakim ST, Kazmi SU. Use of CHROMagar Candida for the presumptive identification of Candida species directly from clinical specimens in resource-limited settings. Libyan J Med. 2010 Feb;9:5. doi: 10.3402/ljm.v5i0.2144, PMID 21483597
Bentz ML, Le N, Min B, Nunnally NS, Sullivan V, Tran M, et al. Evaluation of CHROMagar Candida plus for the detection of C. Auris with a panel of 206 fungal isolates and 83 colonization screening skin-swabs. Microbiol Spectr. 2024 Apr 2;12(4):e0356423. doi: 10.1128/ spectrum.03564-23, PMID 38364098
National Committee for Clinical Laboratory Standards Guidelines. NCCLS M44-A. Method for Antifungal Disk Diffusion Susceptibility Testing of Yeasts; Approved Guideline. Vol. 24; 2004.
Nguyen TB, Tran ND, Lam DT, Do HL, Dinh TH, Nguyen TT, et al. Prevalence of Candida spp. Infect women vaginitis can tho gen hosp. 2022-2023. CTUMP. 2023 Sep 15;63:142-149.
Nguyen Thu H, Vu Huy L, Le Huu D, Ninh Thi D, Tran CV. Prevalence and identification of vaginal Candida species using brilliance candida agar and MALDI-TOF: A comparative study. TC DLH VN. 2023 Nov;9:41.
Alizadeh M, Kolecka A, Boekhout T, Zarrinfar H, Ghanbari Nahzag MA, Badiee P, et al. Identification of Candida species isolated from vulvovaginitis using matrix assisted laser desorption ionization-time of flight mass spectrometry. Curr Med Mycol. 2017 Dec;3(4):21-25. doi: 10.29252/cmm.3.4.21, PMID 29707675
Anh DN, Hung DN, Tien TV, Dinh VN, Son VT, Luong NV, et al. Prevalence, species distribution and antifungal susceptibility of Candida albicans causing vaginal discharge among symptomatic non-pregnant women of reproductive age at a tertiary care hospital, Vietnam. BMC Infect Dis. 2021 Dec;21(1):523. doi: 10.1186/s12879- 021-06192-7, PMID 34082699
Ngo CT, Ton AN. Ification and antifungal resistance of Candida sp. Isolated from patients with vulvovaginal candidoses in Hue University Hospital. Viet J Obstet Gynecol Dent. 2016;13(4):44-47.
Van Leusden HA, Nuijten ST. Miconazole in the treatment of vulvovaginal candidiasis: Comparison of a 6-day therapy and a 3-day treatment course. Eur J Obstet Gynecol Reprod Biol. 1980 Mar;10(3):203-211. doi: 10.1016/0028-2243(80)90061-1, PMID 7189485
Donders G, Sziller IO, Paavonen J, Hay P, De Seta F, Bohbot JM, et al. Management of recurrent vulvovaginal candidosis: Narrative review of the literature and European expert panel opinion. Front Cell Infect Microbiol. 2022 Sep 9;12:934353. doi: 10.3389/fcimb.2022.934353, PMID 36159646
Wang FJ, Zhang D, Liu ZH, Wu WX, Bai HH, Dong HY. Species distribution and in vitro antifungal susceptibility of vulvovaginal candida isolates in China. Chin Med J (Engl). 2016 May 20;129(10):1161-1165. doi: 10.4103/0366-6999.181964, PMID 27174323
Zaman R, Ullah I, Adeeb H, Arif A. Azoles resistance of Candida species causing vulvo-vaginitis in reproductive age women at a tertiary care setting. Pak J Med Sci. 2022 Sep 27;38(8):2239-2245. doi: 10.12669/pjms.38.8.5984, PMID 36415248
Kasper L, Seider K, Hube B. Intracellular survival of Candida glabratain macrophages: Immune evasion and persistence. FEMS Yeast Res. 2015 Aug;15(5):fov042. doi: 10.1093/femsyr/fov042, PMID 26066553
Benedetti VP, Savi DC, Aluizio R, Adamoski D, Kava V, Galli- Terasawa LV, et al. ERG11 gene polymorphisms and susceptibility to fluconazole in Candida isolates from diabetic and kidney transplant patients. Rev Soc Bras Med Trop. 2019;52:e20180473. doi: 10.1590/0037-8682-0473-2018, PMID 30843968
Flowers SA, Barker KS, Berkow EL, Toner G, Chadwick SG, Gygax SE, et al. Gain-of-function mutations in UPC2 are a frequent cause of ERG11 upregulation in azole-resistant clinical isolates of Candida albicans. Eukaryot Cell. 2012 Oct;11(10):1289-1299. doi: 10.1128/EC.00215-12, PMID 22923048
Li J, Coste AT, Bachmann D, Sanglard D, Lamoth F. Deciphering the Mrr1/Mdr1 pathway in azole resistance of Candida auris. Antimicrob Agents Chemother. 2022 Apr 19;66(4):e0006722. doi: 10.1128/ aac.00067-22, PMID 35343781
De Punzio C, Garutti P, Mollica G, Nappi C, Piccoli R, Genazzani AR. Fluconazole 150 mg single dose versus itraconazole 200 mg per day for 3 days in the treatment of acute vaginal candidiasis: A double-blind randomized study. Eur J Obstet Gynecol Reprod Biol. 2003 Feb 10;106(2):193-197. doi: 10.1016/s0301-2115(02)00233-6, PMID 12551791
Sobel JD. Resistance to fluconazole of Candida albicans in vaginal isolates: A 10-year study in a clinical referral center. Antimicrob Agents Chemother. 2023 May 17;67(5):e0018123. doi: 10.1128/aac.00181-23, PMID 37093005
Abosede OO, Ezegwu LE. Synthesis and spectroscopic characterization of silver (I) mebendazole complexes. Int J Chem Res. 2022 Apr 1;6: 1-5. doi: 10.22159/ijcr.2022v6i2.203
Published
How to Cite
Issue
Section
Copyright (c) 2025 Truyen D. Phung, Xiem H. Duong, Son L.Hoang, Thanh Le, Sieu P.M. Tran
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
